Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. About GW Pharmaceuticals plc and Greenwich Biosciences, Inc. What about other medical cannabis products?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

DECEMBER 22, 2021

With growing interest in sustainable and bio-based cannabinoids, and after completing a strategic review of Hyasynth including their intellectual property (IP) and R&D platforms, Organigram remains excited about Hyasynth’s future and growth plans. million of secured convertible debentures in Hyasynth (the “Debentures”).

Cannabinoids 52

Cannabinoids Research and Development Events Pharmaceutical 52

Cannabis Law Report

SEPTEMBER 22, 2021

New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. Chris Chapman, M.D.,

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

JUNE 17, 2021

This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. To have the confidence of DSM in this next round solidifies Brains strategic position within the pharmaceutical industry,” said Brains’ CEO & Chairman Rick Brar.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Events 105

Cannabis Law Report

FEBRUARY 2, 2022

– Flora’s research division, Flora Pharma, files USPTO provisional patent application on a cannabinoid-based formula. – Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under an EUA from INVIMA (Colombian FDA).

Cannabinoids 52

Cannabinoids Clinical Trials Events Cultivation 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Forward-looking statements.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

FEBRUARY 1, 2022

New softgel capsule products further expand ZYUS’ medical cannabinoid offerings and provide patients a precise method for dosing. The launch of these two new softgel products marks another important milestone in ZYUS’ mission to elevate cannabinoids as a standard of care and leverage their transformational potential.

Cannabinoids 52

Cannabinoids Patients Research and Development Media 52

Cannabis Law Report

NOVEMBER 17, 2021

Launch of Zylem ™ 20:1 further expands ZYUS product offerings with new cannabinoid formulation. The launch of this formulation marks an important milestone in ZYUS’ mission to elevate cannabinoids as a standard of care and leverage their transformational potential.

Cannabinoids 52

Cannabinoids Patients Research and Development Extraction 52

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

SEPTEMBER 3, 2021

Flora Lab is acknowledged for its quality procedures which are now in line with global pharmaceutical companies after it receives GMP certification from INVIMA to manufacture cosmetics products. Has the capability to produce cannabinoid-containing products, including cannabidiol (“CBD”). Dietary Supplements. About Flora Growth Corp.

Supply Chain 93

Supply Chain Wellness and Beauty Pharmaceutical Events 93

Cannabis Law Report

OCTOBER 3, 2019

The event will serve as a platform for Icelandic consumers and entrepreneurs to learn about the many potential business opportunities and wellness benefits that hemp and hemp-derived cannabidiol (CBD) could bring to their country. . “Medical Marijuana, Inc. and throughout the world in the past 10 years. billion by 2020.

Events 40

Events Hemp Research and Development Supply Chain 40

FloridaMarijuana.net

AUGUST 15, 2018

Evidence-based Complementary and Alternative Medicine published an article titled “Post-Traumatic Stress Disorder: Evidence-Based Research for the Third Millennium” which describes how profound the symptoms of PTSD can be: “Traumatic events are profoundly stressful. Women tend to experience different traumas than men.

Treatment 182

Treatment Marijuana Research and Development Therapy 182

Cannabis Law Report

OCTOBER 19, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Cannabis Law Report

JUNE 15, 2021

This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. To have the confidence of DSM in this next round solidifies Brains strategic position within the pharmaceutical industry,” said Brains’ CEO & Chairman Rick Brar.

Pharmaceutical 82

Pharmaceutical Clinical Trials Research and Development Events 82

Cannabis Law Report

JULY 26, 2021

VANCOUVER, British Columbia, July 26, 2021 (GLOBE NEWSWIRE) — BC Craft Supply Co Ltd., ( CSE: CRFT ) (“ CRFT ” or the “ Company ”), a diversified wellness company advancing cannabinoid and psychedelic innovation and psychotherapy, is pleased to announce that its subsidiary, FeelWell Brands Inc. About BC Craft Supply Co Ltd.

Events 105

Events Cannabinoids Advocacy Cannabis 105

Cannabis Law Report

JUNE 28, 2021

Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. Zambon is a multinational pharmaceutical company that focuses on innovation and development with the aim to improve patients’ lives. The market for medical cannabis in Germany.

Access 105

Access Research and Development Pharmaceutical Therapy 105

Cannabis Law Report

JANUARY 16, 2020

Devonian” or the “Corporation”) (TSXv:GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today the signature of a lease Agreement with Hzb Pharma Canada Inc. Tweet this.

Extraction 64

Extraction Pharmaceutical Research and Development Terpenes 64

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.).

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Canna Law Blog

OCTOBER 31, 2019

I recently attended two events in Utah headlined by the United Natural Products Alliance (“UNPA”) where its President, Loren Israelsen , discussed the voluminous public comments received by the FDA in response its latest round of questions regarding how over-the-counter cannabis extracts like CBD should be regulated.

Pharmaceutical 54

Pharmaceutical Research and Development Cannabinoids Food 54

CannaMD

FEBRUARY 19, 2020

Medical Marijuana: More Effective Than Pharmaceuticals? To date, there is no pharmaceutical product targeted specifically for the treatment of PTSD. In fact, PTSD treatments based on pharmaceutical antidepressants have been shown to provide just a 60% overall response rate, with only 20 to 30% of patients achieving full remission.

CBD 92

CBD Pharmaceutical Research and Development Conditions 92

Cannabis Law Report

NOVEMBER 23, 2019

for the production R&D of pharmaceutical grade standardised cannabis. Here the company shares their evolution with Health Europa, exploring the production of pharmaceutical grade standardised cannabis. KANNABEIRA® is a project and a registered trademark under the company Green Donation, Ltd. KANNABEIRA and standardised cannabis.

Pharmaceutical 45

Pharmaceutical Research and Development Cultivation Environment 45

Cannabis Law Report

AUGUST 14, 2021

Mary AG’s joint venture Yunnan Moquan and CBDer are currently the only companies licensed for indoor industrial hemp cultivation in China’s only legalized province for cannabinoid extraction. The MOU mainly encompasses: Working with CBDer to further develop China’s industrial hemp market.

Hemp 105

Hemp Supply Chain Cannabinoids Extraction 105

Cannabis Law Report

OCTOBER 21, 2021

Flora Lab serves as Flora Growth’s manufacturing and research and development division for pharmaceuticals, cosmetics, and nutraceuticals. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. About Flora Growth Corp.

Wellness and Beauty 52

Wellness and Beauty Research and Development Events Pharmaceutical 52

Cannabis Law Report

JUNE 10, 2021

Alexis Abraham , Cellular Goods Chief Executive Officer, said: “Successful products start with the best ingredients and being able to source consistent, highly-pure cannabinoids via cellular agriculture from a trusted provider like Willow is essential to our business. ” About Cellular Goods PLC. Cellular Goods is a U.K.-based

Research and Development 66

Research and Development Cannabinoids Pharmaceutical Policy 66

The Cannigma

OCTOBER 2, 2022

But what about CBD , which is usually considered the “more medical” cannabinoid? In a 2020 study on cannabinoids and vomiting, researchers split the group into two: a group that took antiemetic pharmaceuticals and a group that took a CBD/ THC blend. CBDA and nausea. CBDA, or cannabidiolic acid , is the acidic precursor to CBD.

Terpenes 113

Terpenes Strains THC Oil 113

Cannabis Law Report

NOVEMBER 11, 2021

F) (the “Company” or “Canntab” ), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it has received its medical sales license from Health Canada for its Markham, Ontario facility, enabling the sale of all products directly to medical consumers.

Events 52

Events Pharmaceutical Cannabinoids Patients 52

Cannabis Law Report

AUGUST 12, 2022

Drug policy topics have become a consistent feature of the Austin-based event in recent years as more states have legalized cannabis and moved to reform laws around psychedelics like psilocybin locally and at the state level. Mainstreaming Cannabinoids – Path To Legalization. Psychedelics in the Healthcare System.

Research and Development 52

Research and Development Events Topical Policy 52

Cannabis Law Report

SEPTEMBER 27, 2021

Jodi Brichan is a commercialization expert with more than 25 years of experience in bringing new products to market in hypergrowth healthcare industries such as pharmaceuticals, medical devices, energy devices, and life sciences.

Research and Development 52

Research and Development Pharmaceutical Business Events 52

Cannabis Law Report

OCTOBER 25, 2021

Paired with the recent Colombian law change, Flora may now export its high-quality dry flower to international GMP active pharmaceutical ingredient (“API”) producers or to markets where flower can be imported. “In Cosechemos Operational Update. per gram of dried flower. Forward-looking statements are only predictions.

Agriculture 52

Agriculture Collective Events Pharmaceutical 52

Cannabis Law Report

SEPTEMBER 3, 2019

(TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce that its subsidiary MediPharm Labs Australia Pty. Gaining Momentum in Australia: Facility Construction Update.

Pharmaceutical 45

Pharmaceutical Extraction Research and Development Supply Chain 45

Cannabis Law Report

FEBRUARY 3, 2022

Nimbus Health is a privately owned, licensed pharmaceutical wholesaler from Germany focusing on medical cannabis in Germany. Reddy’s commitment sets a significant milestone for further developing medical cannabinoid-based medicines and unlocking new possibilities to benefit patients. About Nimbus Health GmbH.

Pharmaceutical 52

Pharmaceutical Events Patients Medicine 52

The Cannigma

OCTOBER 9, 2021

Studies demonstrate that cannabis and its cannabinoid constituents have an implication on human urinary function. The common understanding is that every individual has a separate and different reaction to cannabinoid-based therapy, the same is true with how it might influence individual urinary symptoms.

Cannabinoids 86

Cannabinoids Consumption Patients Cannabis 86

Cannabis Law Report

JANUARY 11, 2022

The new facility is fully automated and features cryo-ethanol extraction that yields economical and high-quality cannabinoid derivatives at high-throughput. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us.

Extraction 52

Extraction Wellness and Beauty Events Cultivation 52

Cannabis Law Report

OCTOBER 19, 2021

This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Medical Marijuana, Inc. to be materially different from the statements made herein.

Research and Development 52

Research and Development Supply Chain Marijuana Cannabinoids 52

Cannabis Law Report

JUNE 15, 2021

The Customer intends to use PharmaCielo’s Active Pharmaceutical Ingredients (APIs) for expanded research and development of their innovative, proprietary sublingual product platform. These forward-looking statements relate to future events or the Company’s future performance. and Canada. ” About PharmaCielo.

Research and Development 66

Research and Development Supply Chain Extraction Events 66

Cannabis Law Report

OCTOBER 9, 2019

(TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce its participation at the BMO & TMX Hemp & Medical Cannabis Conference in London, UK on October 16, 2019.

Hemp 40

Hemp Extraction Events Cannabinoids 40